



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/718,725	11/22/2000	William J. Boyle	A-378CIP2C3	5057

7590 04/02/2003
AMGEN INC
M/S 27-4-A
ONE AMGEN CENTER DRIVE
THOUSAND OAKS, CA 91320

EXAMINER

DEBERRY, REGINA M

ART UNIT PAPER NUMBER

1647

DATE MAILED: 04/02/2003

12

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	09/718,725	BOYLE ET AL.
Examiner	Art Unit	
Regina M. DeBerry	1647	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 14 January 2003.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 61-75 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 61,63,65 and 69-75 is/are rejected.

7) Claim(s) 62,64 and 66-68 is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.
 If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
 * See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
 a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s). _____.
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) Notice of Informal Patent Application (PTO-152)
 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____. 6) Other: _____

Status of Application, Amendments and/or Claims

The amendment filed 18 December 2002 (Paper No. 10) has been entered in full.

Claims 1-60 were cancelled. New claims 61-75 were added.

Applicant has stated that the title will be amended upon indication of allowable subject matter.

The application fully complies with the sequence rules 37 CFR 1.821-1.825.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Withdrawn Objections And/Or Rejections

The objection to the specification as set forth at page 3 of the previous Office Action (19 June 2002, Paper No. 7) is *withdrawn* in view of the amendment (18 December 2002, Paper No. 10).

The rejection of claims 39-41 under 35 USC 112, first paragraph, scope of enablement, as set forth at pages 3-5 of the previous Office Action (19 June 2002, Paper No. 7) is *withdrawn* in view of the amendment (18 December 2002, Paper No. 10).

The rejection of claims 39-41 under 35 USC 112, second paragraph, as set forth at page 5 of the previous Office Action (19 June 2002, Paper No. 7) is *withdrawn* in view of the amendment (18 December 2002, Paper No. 10).

Claim Objections

Claims 62, 64, 66-68 are objected to because they depend from a rejected claim.

Claim Rejections - 35 USC § 112, First Paragraph, scope of enablement

Claims 61, 63, 65, 69-75 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for an antibody or fragment thereof which binds at least a portion of the amino acid sequence of SEQ ID NO:121 wherein said portion comprises an epitope, does not reasonably provide enablement for an antibody or fragment thereof which binds an epitope comprising at least a portion of the amino acid sequence of SEQ ID NO:121. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.

An antibody or fragment thereof which binds an epitope comprising at least a portion of SEQ ID NO:121 is different from an antibody or fragment thereof which binds at least a portion of the amino acid sequence of SEQ ID NO:121 wherein said portion comprises an epitope. The instant claims do not specify that the recited epitope is an epitope of SEQ ID NO:121. The claims, as recited, will give rise to antibodies that are not specific for SEQ ID NO:121. The specification teaches "antibodies so produced are characterized for binding specificity and epitope recognition..." (specification, page 31, lines 19-21). The specification fails to teach one skilled in the how to use non-specific antibodies. In addition, the undefined epitope contains an undefined portion of SEQ ID

NO:121, such that the claims read on epitopes comprising a single amino acid of SEQ ID NO:121.

Due to the large quantity of experimentation necessary to use non-specific antibodies, the lack of direction/guidance presented in the specification regarding same, the absence of working examples directed to same, the complex nature of the invention, and the breadth of the claims which fail to recite structural limitations, undue experimentation would be required of the skilled artisan to make and/or use the claimed invention in its full scope.

Conclusion

No claims are allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

Art Unit: 1647

the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Regina M. DeBerry whose telephone number is (703) 305-6915. The examiner can normally be reached on 9:00 a.m.-6:00 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz can be reached on (703) 308-4623. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 872-9306 for regular communications and (703) 872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Elizabeth C. Lemmon

RMD

RMD
March 27, 2003